help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 18, 2008
Molecular Endocrinology, doi:10.1210/me.2007-0581
A more recent version of this article appeared on September 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
22/9/2061    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Holmstrom, S. R.
Right arrow Articles by Iñiguez-Lluhí, J. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmstrom, S. R.
Right arrow Articles by Iñiguez-Lluhí, J. A.

Submitted on December 26, 2007
Accepted on June 11, 2008

SUMO-MEDIATED INHIBITION OF GLUCOCORTICOID RECEPTOR SYNERGISTIC ACTIVITY DEPENDS ON STABLE ASSEMBLY AT THE PROMOTER BUT NOT ON DAXX

Sam R. Holmstrom, Sergey Chupreta, Alex Yick-Lun So, and Jorge A. Iñiguez-Lluhí*

Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-0632; and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143-2280

* To whom correspondence should be addressed. E-mail: iniguez{at}umich.edu.

Multiple transcription factors, including members of the nuclear receptor family harbor one or more copies of a short regulatory motif that limits synergistic transactivation in a context-dependent manner. These Synergy Control or SC motifs exert their effects by serving as sites for post-translational modification by Small Ubiquitin like Modifier (SUMO) proteins. By analyzing the requirements for both synergy control and SUMOylation in the glucocorticoid receptor (GR), we find that an intact ligand-binding domain (LBD) and an engaged DNA binding domain (DBD) dimerization interface are necessary for effective synergy control. However, these features, which promote stable assembly of GR-DNA complexes, are required downstream of SUMOylation since their disruption or deletion does not interfere with SUMO modification. Remarkably, in the absence of these features, sensitivity to the effects of SUMOylation can be restored simply by stabilization of DNA interactions through a heterologous DNA binding domain. The data indicate that stable interaction with DNA is an important prerequisite for SUMO-dependent transcriptional inhibition. Analysis of genomic regions occupied by GR indicates that the effects of SC motif SUMOylation are most evident at multiple, near-ideal GR binding sites and that SUMOylation selectively affects the induction of linked endogenous genes. Although the SUMO-binding protein DAXX has been proposed to mediate the inhibitory effects of GR SUMOylation, we find that inhibition by DAXX is independent of GR SUMOylation. Furthermore, neither expression nor knockdown of DAXX influences SUMO effects on GR. We therefore propose that stable binding of GR to multiple sites on DNA allows for the SUMO-dependent recruitment of inhibitory factors distinct from DAXX.


Key words: Synergy Control • SUMO • Glucocorticoid Receptor • FKBP5 • DAXX • 0

NURSA Molecule Pages Link:

Nuclear Receptors:   GR
Ligands:   Dexamethasone






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society